Mahler Hanns-Christian, Friess Wolfgang, Grauschopf Ulla, Kiese Sylvia
Formulation R&D Biologics, Pharmaceutical and Analytical R&D, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
J Pharm Sci. 2009 Sep;98(9):2909-34. doi: 10.1002/jps.21566.
Control and analysis of protein aggregation is an increasing challenge to pharmaceutical research and development. Due to the nature of protein interactions, protein aggregation may occur at various points throughout the lifetime of a protein and may be of different quantity and quality such as size, shape, morphology. It is therefore important to understand the interactions, causes and analyses of such aggregates in order to control protein aggregation to enable successful products. This review gives a short outline of currently discussed pathways and induction methods for protein aggregation and describes currently employed set of analytical techniques and emerging technologies for aggregate detection, characterization and quantification. A major challenge for the analysis of protein aggregates is that no single analytical method exists to cover the entire size range or type of aggregates which may appear. Each analytical method not only shows its specific advantages but also has its limitations. The limits of detection and the possibility of creating artifacts through sample preparation by inducing or destroying aggregates need to be considered with each method used. Therefore, it may also be advisable to carefully compare analytical results of orthogonal methods for similar size ranges to evaluate method performance.
蛋白质聚集的控制与分析对药物研发而言是一项日益严峻的挑战。由于蛋白质相互作用的特性,蛋白质聚集可能在蛋白质整个生命周期的不同阶段发生,且聚集物的数量和质量各异,比如大小、形状、形态等。因此,了解此类聚集体的相互作用、成因及分析方法,对于控制蛋白质聚集以研发出成功的产品至关重要。本综述简要概述了当前讨论的蛋白质聚集途径和诱导方法,并描述了目前用于聚集体检测、表征和定量的一系列分析技术及新兴技术。蛋白质聚集体分析面临的一个主要挑战是,不存在单一的分析方法能涵盖可能出现的所有大小范围或类型的聚集体。每种分析方法不仅有其特定优势,也有其局限性。使用每种方法时都需考虑检测限以及通过诱导或破坏聚集体的样品制备过程产生假象的可能性。因此,仔细比较相似大小范围的正交方法的分析结果以评估方法性能或许也是明智之举。